BIO-TECHNE Corp Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
BIO-TECHNE Corp (TECH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.59% for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-24
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2012-09-30 was 1.50%, a 7.14% increase year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2012-03-31 was 1.60%.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2011-12-31 was 1.60%, a 11.11% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2011-09-30 was 1.40%, a 22.22% decline year-over-year.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2026 was 0.59%, a 31.11% increase from fiscal 2025.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.45%, a 9.76% increase from fiscal 2024.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.41%, a 20.59% increase from fiscal 2023.
- BIO-TECHNE Corp share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.34%, a 25.93% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | 0.59% 10-K · filed 2026-08-24 | ||||
| 2025-06-30 | 0.45% 10-K · filed 2026-08-24 | ||||
| 2024-06-30 | 0.41% 10-K · filed 2026-08-24 | ||||
| 2023-06-30 | 0.34% 10-K · filed 2025-08-22 | ||||
| 2022-06-30 | 0.27% 10-K · filed 2024-08-22 | ||||
| 2021-06-30 | 0.47% 10-K · filed 2023-08-23 | 0.24% 10-K · filed 2021-08-25 | |||
| 2020-06-30 | 0.67% 10-K · filed 2022-08-24 | ||||
| 2019-06-30 | 0.74% 10-K · filed 2021-08-25 | ||||
| 2018-06-30 | 1.10% 10-K · filed 2020-08-26 | ||||
| 2017-06-30 | 1.20% 10-K/A · filed 2019-11-06 | ||||
| 2016-06-30 | 1.20% 10-K · filed 2018-08-27 | ||||
| 2015-06-30 | 1.30% 10-K · filed 2017-09-07 | ||||
| 2014-06-30 | 1.50% 10-K · filed 2016-08-29 | ||||
| 2013-06-30 | 1.80% 10-K · filed 2015-08-31 | ||||
| 2012-09-30 | 1.50% 10-Q · filed 2012-11-09 | ||||
| 2012-06-30 | 1.50% 10-K · filed 2014-08-29 | ||||
| 2012-03-31 | 1.60% 10-Q · filed 2012-05-10 | 1.50% 10-Q · filed 2012-05-10 | |||
| 2011-12-31 | 1.60% 10-Q · filed 2012-02-07 | 1.50% 10-Q · filed 2012-02-07 | |||
| 2011-09-30 | 1.40% 10-Q · filed 2012-11-09 | ||||
| 2011-06-30 | 1.50% 10-K · filed 2013-08-29 | ||||
| 2011-03-31 | 1.80% 10-Q · filed 2012-05-10 | ||||
| 2010-12-31 | 1.80% 10-Q · filed 2012-02-07 | 1.80% 10-Q · filed 2012-02-07 | |||
| 2010-09-30 | 1.80% 10-Q · filed 2011-11-09 | ||||
| 2010-06-30 | 1.60% 10-K · filed 2012-08-29 | ||||
| 2009-06-30 | 1.60% 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |